<DOC>
	<DOCNO>NCT01071876</DOCNO>
	<brief_summary>Multicenter randomize double blind study versus placebo 12 week first , escalate dose period follow stable dose period select dose . This double-blind period follow 9 month open-label period patient wish continue study product .</brief_summary>
	<brief_title>BF2.649 Patients With OSA Treated CPAP But Still Complaining EDS</brief_title>
	<detailed_description>The first period ( 12 week double blind period ) aim demonstrate efficacy safety BF2.649 verify whether result BF2.649 superior placebo . The aim second period ( open label extension phase ) ass long-term tolerance , well maintenance BF2.649 efficacy .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>patient OSA treat nCPAP still complain EDS ESS score &gt; = 12 patient suffer insomnia without OSA coexist narcolepsy patient sleep debt due OSA acute chronic severe disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Sleep disorder</keyword>
	<keyword>obstructive sleep apnea</keyword>
	<keyword>excessive daytime sleepiness</keyword>
	<keyword>patient OSA treat CPAP present EDS</keyword>
</DOC>